Home/Pipeline/Firdapse® (amifampridine phosphate)

Firdapse® (amifampridine phosphate)

Lambert-Eaton Myasthenic Syndrome (LEMS)

ApprovedCommercial

Key Facts

Indication

Lambert-Eaton Myasthenic Syndrome (LEMS)

Phase

Approved

Status

Commercial

Company

Dydo Pharma

About Dydo Pharma

Japanese pharmaceutical company specializing in rare neurological disease treatments, with recent approval of Firdapse® for Lambert-Eaton myasthenic syndrome in Japan.

View full company profile

Therapeutic Areas

Neurology

Other Lambert-Eaton Myasthenic Syndrome (LEMS) Drugs

Drug	Company	Phase	Status
FIRDAPSE (amifampridine)	Catalyst Pharmaceuticals	Marketed	Commercial